GLP-1 Market
LLY $1431.76 ▼ -0.0% NVO $40.82 ▲ +0.3% PFE $29.23 ▼ -0.5% VKTX $28.92 ▲ +0.9% KLRA $14.29 ▲ +0.4% GPCR $21.30 ▼ -2.0% RHHBY $61.06 ▼ -0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Veverimer

Company
Renibus Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Veverimer and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07355062

    A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

    Not yet reported Renibus Therapeutics, Inc. 150 participants Est. completion 2027-06 28 sites Stand-alone
    Chronic kidney disease Other conditions: Metabolic Acidosis
    View official trial listing →
  • Recruiting NCT NCT07473713

    Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

    Not yet reported Tufts Medical Center 60 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Osteopenia
    View official trial listing →
  • Completed NCT NCT02809183

    Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

    Not yet reported, Not yet reported Tricida, Inc. 135 participants Est. completion 2016-11 5 sites
    Other conditions: Acidosis
    View official trial listing →
  • Completed NCT NCT03317444

    Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

    Not yet reported Tricida, Inc. 217 participants Est. completion 2018-05-15 44 sites
    Other conditions: Metabolic Acidosis
    View official trial listing →
  • Completed NCT NCT03390842

    Long-term Safety Extension to Study TRCA-301

    Not yet reported Tricida, Inc. 196 participants Est. completion 2019-02-22 29 sites
    Other conditions: Metabolic Acidosis
    View official trial listing →
  • Terminated NCT NCT03710291

    Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

    Not yet reported Tricida, Inc. 1480 participants Est. completion 2022-09-27 203 sites
    Chronic kidney disease Other conditions: Metabolic Acidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Veverimer, veverimer daily

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.